摘要
目的 了解国家抗肿瘤药医保谈判相关政策落地后,我院这类药品的临床应用情况及变化趋势,为医院药品目录优化与调整提供参考。方法 收集2019~2021年全院国谈抗肿瘤药的数据。对品种、销售金额、用药频度(DDDs)、限定日费用(DDC)以及药品的销售金额和用药频度的排序比值(B/A)等情况进行统计分析。结果 2019~2021年医院国谈抗肿瘤药物的品种数、药品销售金额以及用药频度呈逐年上升趋势,曲妥珠单抗的销售金额、DDDs连续三年居第一位。用药金额排名前3位的病种分别为乳腺癌、胃肠道肿瘤和肺癌;用药金额排名前3位的药物分别为曲妥珠单抗、贝伐珠单抗、奥希替尼,且用药金额与用药频度、限定日费同步性好;2020年度、2021年度的用药金额分别同比增加65.84%、49%,用药频度分别同比增长56.16%、69.36%。结论 国家医保谈判政策促进了抗肿瘤药在临床的使用,提高了患者用药可及性,亦导致医院的药品费用大幅度增长。应加强对相关药品的临床应用监测和动态评估,在保障患者用药需求的同时促进合理用药。医院国谈抗肿瘤药的用药现状及倾向基本符合我国当前药物消耗总趋势。
OBJECTIVE Investigating the clinical application situation and changing trend of national negotiation antineoplastic drugs in our hospital after the implementation of relevant policies insurance negotiation,so as to provide reference for the optimization and adjustment of hospital drug list.METHODS The data of national negotiation antineoplastic drugs from 2019 to 2021 were collected.The variety,sales amount,DDDs,daily average cost(DDC)and the sorting ratio(B/A)were analyzed.RESULTS In the year of 2019 to 2021,the varieties,sales amount and DDDs of national negotiation antineoplastic drugs showed an increasing trend year by year,and the trastuzumab was the first in sales amount,DDDs for three consecutive years.The national negotiation antineoplastic drugs were mainly used for breast cancer,gastrointestinal tumor and lung cancer.The top three antineoplastic drugs in terms of cost were trastuzumab,bevacizumab and ocitinib,with good synchronization of drug consumption,DDDs and DDC.In 2020 and 2021,sales amount increased by 65.84%and 49%,and drug frequency increased by 56.16%and 69.36%,respectively.CONCLUSION The national health insurance negotiation policy promot the use of antineoplastic drugs,improve the accessibility of these drugs to patients,and also lead the substantial increasing of drug costs in hospital.The current situation and tendency of antineoplastic drugs use in our hospital are basically in line with the general trend of drugs consumption.
作者
陈春枚
林文宏
赵志斌
陈东风
占鹏
饶媚
CHEN Chun-mei;LIN Wen-hong;ZHAO Zhi-bin;CHEN Dong-feng;ZHAN-peng;RAO Mei(Department of Pharmacy,Longyan First Hospital Affiliated of Fujian Medical University,Longyan 364000,China;Department of Orthopedics,Longyan First Hospital Affiliated of Fujian Medical University,Longyan 364000,China)
出处
《海峡药学》
2023年第4期62-66,共5页
Strait Pharmaceutical Journal
基金
龙岩市科技计划项目(编号2019LYF12008)。
关键词
抗肿瘤药
国家医保谈判
用药频度
用药金额
Antineoplastic drugs
National medical insurance negotiations
Drug frequency
Drug amount
